We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

INDIANAPOLIS — When you are out shopping, you often see labels showing where the product is made. But look at your generic medication and there is a good chance the "made in" line is missing. Dr.

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...

Generic drug manufacturers are facing increasing pressure from drug distributors, pharmacy benefit managers, and Indian competitors, leading to downward trends in generic drug prices. Which firms are ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

June 24 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab said on Monday it had launched a generic version of Novo Nordisk's (NOVOb.CO), opens new tab Victoza to treat patients with type 2 ...

Walgreens said Wednesday that it will sell its own generic version of over-the-counter Narcan, the lifesaving opioid overdose reversal drug that first rolled out to drugstore shelves last fall. Its ...

AstraZeneca (NASDAQ:AZN) plans to cap out-of-pocket costs for its inhaler medications at $35 per month following Congressional criticism of the company's pricing of the products in the US. The cap, ...

Starting June 1, Boehringer Ingelheim plans to cap inhaler products for respiratory diseases at $35 per month for eligible patients. Boehringer Ingelheim announced plans to limit the out-of-pocket ...

WASHINGTON, D.C. -- Inhaler manufacturer Boehringer Ingelheim will cap the out-of-pocket price of its inhalers following an investigation by a Senate committee, Sen. Tammy Baldwin announced Thursday.